Clinical outcome after surgical resection of lung metastases from melanoma

被引:9
作者
Conill, Carlos [1 ]
Maria Gimferrer, Jose [2 ]
Marruecos, Jordi [1 ]
Domingo-Domenech, Josep [3 ]
Vilella, Ramon [4 ]
Catalan, Miquel [2 ]
Malvehy, Josep [3 ]
Puig, Susana [4 ]
Castel, Teresa [4 ]
机构
[1] Univ Barcelona, IDIBAPS, Hosp Clin, Inst Hematol & Oncol,Dept Radiat Oncol, Barcelona 08036, Spain
[2] Univ Barcelona, IDIBAPS, Hosp Clin, Inst Hematol & Oncol,Dept Thorac Surg, Barcelona 08036, Spain
[3] Univ Barcelona, IDIBAPS, Hosp Clin, Inst Hematol & Oncol,Dept Med Oncol, Barcelona 08036, Spain
[4] Univ Barcelona, IDIBAPS, Hosp Clin, Inst Hematol & Oncol,Dept Immunol & Dermatol, Barcelona 08036, Spain
关键词
lung; melanoma; metastasis; surgery treatment;
D O I
10.1007/s12094-007-0009-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Surgical therapy plays an important role in the management of selected patients with metastatic melanoma. Purpose. A retrospective review of 13 patients who underwent surgical resection of lung metastases from melanoma from 1996 to 2003 was performed. The aim of the study was to analyze the clinical outcome and survival time. Materials and methods. Mean age was 45 years old ( range: 31-64). Complete tumour resection was confirmed histologically. Nine patients presented one single pulmonary lesion, two lesions (n = 3) and three lesions ( n = 1) but in all cases confined in the same pulmonary lobe. Results. Median survival time (MST) for the entire group was 20 months (95% confidence interval (CI): 16-24 months). The median time to disease progression after lung metastasectomy was 5 months ( 95% CI: 3-7 months). MST, according to the prognostic groups proposed by the International Registry of Lung Metastases, was 17 months ( 95% CI: 6-28 months) for group I ( n = 6), MST of 20 months ( 95% CI: 16-24 months) for group II ( n = 5) and MST of 4 months for group III ( n = 2), without differences statistically significant (log-rank p = 0.423). MST regarding the time of disease free interval from diagnostic of primary tumour and lung metastases (< 36 months [ n = 5] vs >\ 36 months [ n = 8]) was 20 months and 17 months respectively, without differences statistically significant ( log rank p = 0.222). Conclusions. Surgical resection when feasible provides survival rates superior to any available nonsurgical therapy. In carefully selected patients, when the resection is performed with curative intent, it may result in improved survival.
引用
收藏
页码:48 / 52
页数:5
相关论文
共 25 条
[1]   A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy [J].
Finkelstein, SE ;
Carrasquillo, JA ;
Hoffman, JM ;
Galen, B ;
Choyke, P ;
White, DE ;
Rosenberg, SA ;
Sherry, RM .
ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (08) :731-738
[2]   IMPROVED SURVIVAL AFTER RESECTION OF PULMONARY METASTASES FROM MALIGNANT-MELANOMA [J].
GORENSTEIN, LA ;
PUTNAM, JB ;
NATARAJAN, G ;
BALCH, CA ;
ROTH, JA .
ANNALS OF THORACIC SURGERY, 1991, 52 (02) :204-210
[3]  
HARPOLE DH, 1992, J THORAC CARDIOV SUR, V103, P743
[4]   Impact of 2-deoxy-2[F-18]fluoro-D-glucose positron emission tomography on the management of patients with advanced melanoma [J].
Harris, MT ;
Berlangieri, SU ;
Cebon, JS ;
Davis, ID ;
Scott, AM .
MOLECULAR IMAGING AND BIOLOGY, 2005, 7 (04) :304-308
[5]   Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine [J].
Hsueh, EC ;
Essner, R ;
Foshag, LJ ;
Ollila, DW ;
Gammon, G ;
O'Day, SJ ;
Boasberg, PD ;
Stern, SL ;
Ye, X ;
Morton, DL .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (23) :4549-4554
[6]   The role of surgery in lung metastases [J].
Kolodziejski, L ;
Góralczyk, J ;
Dyczek, S ;
Duda, K ;
Nabialek, T .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1999, 25 (04) :410-417
[7]   Lung metastases from melanoma: when is surgical treatment warranted? [J].
Leo, F ;
Cagini, L ;
Rocmans, P ;
Cappello, M ;
Van Geel, AN ;
Maggi, G ;
Goldstraw, P ;
Pastorino, U .
BRITISH JOURNAL OF CANCER, 2000, 83 (05) :569-572
[8]  
MARINCOLA FM, 1990, ARCH SURG-CHICAGO, V125, P1387
[9]  
Meyer T, 2000, CANCER, V89, P1983, DOI 10.1002/1097-0142(20001101)89:9<1983::AID-CNCR15>3.3.CO
[10]  
2-J